<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrent <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in splicing machinery components, including SF3B1, U2AF1 and SRSF2 genes have recently been reported in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Such a recurrent nature strongly suggests that these mutations play important roles in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="2" pm="."><plain>To see whether SF3B1, U2AF1 and SRSF2 mutations occur in other human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> besides <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we analyzed the hotspot mutation regions of these genes in 2,345 tumor tissues from various origins (61 MDS, other 616 hematologic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 1,421 epithelial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 247 non-epithelial <z:e sem="disease" ids="C0879615" disease_type="Neoplastic Process" abbrv="">stromal tumors</z:e>) by single-strand conformation polymorphism analysis </plain></SENT>
<SENT sid="3" pm="."><plain>We found SF3B1, U2AF1 and SRSF2 mutations in 5 (8.2%), 12 (19.7%) and 8 (13.1%) of 61 MDS, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>We also confirmed these mutations in other myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, including de novo <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, we discovered that the SRSF2 gene was mutated in two childhood <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (<z:e sem="disease" ids="C0023452" disease_type="Neoplastic Process" abbrv="">childhood ALL</z:e>) (1.5%) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, we found SF3B1 mutations in gastric and <z:hpo ids='HP_0012125'>prostate cancers</z:hpo>, and U2AF1 mutation in a borderline <z:e sem="disease" ids="C1335168" disease_type="Neoplastic Process" abbrv="">mucinous tumor of ovary</z:e>, but the overall incidences of the hotspot mutation regions were very low (0.2%) </plain></SENT>
<SENT sid="7" pm="."><plain>Our data suggest that SF3B1, U2AF1 and SRSF2 mutations occur not only in myeloid lineage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> but also in lymphoid lineage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The data suggest that the splicing gene mutations play important roles in the pathogenesis of hematologic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, but rarely in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
</text></document>